ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "New Therapeutics"

  • Abstract Number: 1497 • 2014 ACR/ARHP Annual Meeting

    Efficacy and Safety of Iguratimod for Rheumatoid Arthritis

    Tsuneo Kondo1, Akiko Shibata1, Ryota Sakai1, Kentaro Chino1, Ayumi Okuyama1, Hirofumi Takei1 and Koichi Amano2, 1Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan, 2Saitama Medical Center, Saitama Medical University, Kawagoe, Japan

    Background/Purpose: Iguratimod is a new small-molecular drug for rheumatoid arthritis (RA), which was approved on June, 2012 in Japan. The agent inhibits the production of…
  • Abstract Number: 14 • 2014 ACR/ARHP Annual Meeting

    Rivaroxaban Use in Patients with Antiphospholipid Syndrome Patients and Previous Poor Anticoagulation Control with Vitamin K Antagonists

    Savino Sciascia1 and Beverley Hunt2, 1Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine, London, United Kingdom, 2St Thomas Hospital, London, UK, Thrombosis and Thrombophilia Center (St Thomas Hospital, London, UK), London, United Kingdom

    Background/Purpose: Management of antiphospholipid syndrome (APS) centres on attenuating the procoagulant state whilst balancing the bleeding risks of anticoagulant therapy. In a minority of APS…
  • Abstract Number: 1838 • 2013 ACR/ARHP Annual Meeting

    The Use Of Three-Dimensionally Printed β-Tricalcium Phosphate/Hydroxyapatite To Understand The Regulation Of Adenosine Receptors In Osteoclast Formation and Promotion In Bone Regeneration

    Stephanie Ishack1, Aranzazu Mediero1, Tuere Wilder2, John Ricci3 and Bruce N. Cronstein4, 1Medicine, Division of Translational Medicine, NYU School of Medicine, New York, NY, 2Medicine, division of Translational Medicine, NYU School of Medicine, New York, NY, 3Biomaterials, NYU Dental School, New York, NY, 4Internal Medicine, NYU School of Medicine, Division of Rheumatology, New York, NY

    Background/Purpose: Bone defects resulting from trauma or infection need timely and effective treatments to replace damaged bone. Using specialized three-dimensional (3-D) printing technology, combined with…
  • Abstract Number: 1792 • 2013 ACR/ARHP Annual Meeting

    Inhibition Of Chemokine Receptors CCR1 and CCR6 As Promising Therapies For Autoimmune Diseases Such As Rheumatoid Arthritis and Psoriasis

    Daniel Dairaghi1, Penglie Zhang2, Manmohan Leleti2, Robert Berahovich3, Karen Ebsworth3, Linda Ertl3, Shichang Miao4, Zhenhua Miao3, Lisa Seitz3, Joanne Tan3, Matthew Walters3, Yu Wang3, Jay Powers5, Thomas J. Schall6 and Juan C. Jaen7, 1Biology, ChemoCentryx, Inc., Mountain View, CA, 2Chemistry, ChemoCentryx, Mountain View, CA, 3Biology, ChemoCentryx, Mountain View, CA, 4Pharmacokinetics, ChemoCentryx, Inc., Mountain View, CA, 5ChemoCentryx, Mountain View, CA, 6ChemoCentryx, Inc., Mountain View, CA, 7Discovery and Preclinical Development, ChemoCentryx, Inc., Mountain View, CA

    Background/Purpose:  Chemokines are key regulators of leukocyte activation and recruitment to sites of inflammation. Of particular relevance in rheumatoid arthritis (RA), the chemokine receptors CCR1…
  • Abstract Number: 1433 • 2013 ACR/ARHP Annual Meeting

    Lack Of Early Clinical Response To Treatment With Baricitinib Predicts Low Probability Of Achieving Long Term DAS28-ESR Low Disease Activity Or Remission In Patients With Rheumatoid Arthritis

    Edward Keystone1, MC Genovese2, Peter Taylor3, Baojin Zhu4, Scott D. Beattie4, Stephanie de Bono4, Terence Rooney4, Douglas E. Schlichting4 and William Macias4, 1University of Toronto, Toronto, ON, Canada, 2Division of Immunology and Rheumatology, Stanford University Medical Center, Palo Alto, CA, 3NDORMS, Botnar Research Centre, University of Oxford, Oxford, United Kingdom, 4Eli Lilly and Company, Indianapolis, IN

    Background/Purpose:   Baricitinib, an oral inhibitor of JAK1 and JAK2 activity, was investigated as treatment for patients with moderately to severely active RA despite use…
  • Abstract Number: L11 • 2012 ACR/ARHP Annual Meeting

    First in Patient Study of Anti-GM-CSF Monoclonal Antibody (MOR103) in Active Rheumatoid Arthritis: Results of a Phase 1b/2a Randomized, Double-Blind, Placebo-Controlled Trial

    Frank Behrens1, Mikkel Ostergaard2, Rumen Stoilov3, Piotr Wiland4, Thomas W. Huizinga5, Vadym Y. Berenfus6, Paul-Peter Tak7, Stoyanka Vladeva8, Juergen Rech9, Andrea Rubbert-Roth10, Mariusz Korkosz11, Dmitriy Rekalov12, Igor A. Zupanets13, Bo J. Ejbjerg14, Jens Geiseler15, Julia Fresenius15, Roman P. Korolkiewicz16, Arndt J. Schottelius16 and Harald Burkhardt1, 1CIRI /Div. of Rheumatology, Goethe-University, Frankfurt/Main, Germany, 2Copenhagen Center for Arthritis Research, Copenhagen University Hospital at Glostrup, Glostrup, Denmark, 3Clinic of rheumatology, University Hospital (MHAT) St. Ivan Rilski, Sofia, Bulgaria, 4Department of Rheumatology, Medical University of Wroclaw, Wroclaw, Poland, 5Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 6Occupational Diseases, Regional Clinical Hospital, Donetsk, Ukraine, 7Academic Medical Center / currently also GlaxoSmithKline, Amsterdam, Netherlands, 8Second Internal Clinic UMHAT Stara Zagora, Stara Zagora, Bulgaria, 9Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, 10Internal Medicine I, University of Cologne, Cologne, Germany, 11Malopolskie Centrum Medyczne, Krakow, Poland, 12Department of Internal Diseases, Zaporizhzhia Regional Hospital, Zaporozhe, Ukraine, 13Clinical and Diagnostics Centre of National Pharmaceutical University MOH of Ukraine, Kharkiv, Ukraine, 14Slagelse Sygehus, Slagelse, Denmark, 15Asklepios Clinic Munich-Gauting, Gauting, Germany, 16Development, MorphoSys AG, Martinsried/Planegg, Germany

    Background/Purpose: MOR103, a human mAb targeting GM-CSF, is being evaluated for treatment of rheumatoid arthritis (RA). Pre-clinical studies on cytokine function and investigations in experimental…
  • « Previous Page
  • 1
  • 2
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology